PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.02
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$82.68

03 Oct
2023

-1.130

OPEN

$83.22

-1.35%

HIGH

$84.00

250,752

LOW

$82.07

TARGET
$63.625 -23.0% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MEB . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 58.1 76.1 xxx
DPS (cps) xxx 30.0 38.6 xxx
EPS Growth xxx 36.4% 30.9% xxx
DPS Growth xxx 36.4% 28.7% xxx
PE Ratio xxx N/A 108.3 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 51.6% 50.8% xxx

Dividend yield today if purchased 3 years ago: 1.14%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.36

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 17c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx58.1
DPS All xxxxxxxxxxxxxxx30.0
Sales/Revenue xxxxxxxxxxxxxxx124.9 M
Book Value Per Share xxxxxxxxxxxxxxx132.9
Net Operating Cash Flow xxxxxxxxxxxxxxx64.8 M
Net Profit Margin xxxxxxxxxxxxxxx48.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx50.43 %
Return on Invested Capital xxxxxxxxxxxxxxx49.84 %
Return on Assets xxxxxxxxxxxxxxx33.77 %
Return on Equity xxxxxxxxxxxxxxx50.43 %
Return on Total Capital xxxxxxxxxxxxxxx68.57 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx38.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx121 M
Price To Book Value xxxxxxxxxxxxxxx49.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx6.4 M
Capex % of Sales xxxxxxxxxxxxxxx5.16 %
Cost of Goods Sold xxxxxxxxxxxxxxx33 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.3

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

27/09/2023

5

Sell

$33.50

-59.48%

Ord Minnett raises the target by 8% to $33.50 given an uplift in contracted revenue for Pro Medicus following a significant contract gain. The contract with Baylor Scott & White Health is for $14m a year over 10 years.

The broker notes this is the latest in an impressive list of academic hospitals that are clients of the company and assumes a six-month earnings contribution in FY24.

The shares still appear materially overvalued and Ord Minnett suspects the market is underestimating the competitive pressures. Sell rating retained.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 39.00 cents and EPS of 77.50 cents.
Ord Minnett forecasts a full year FY25 dividend of 46.00 cents and EPS of 91.90 cents.

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

PME STOCK CHART

FNArena News on PME

1
Rudi’s View: To Sell Or Not To Sell?

10:00 AM - Rudi's View
2
Australian Broker Call *Extra* Edition – Sep 27, 2023

Sep 27 2023 - Daily Market Reports
3
Rudi’s Views: August 2023 – Winners & Losers

Sep 13 2023 - Rudi's View
4
Rudi’s View: Outlook Negative, With Plenty Of Silver Linings

Sep 06 2023 - Rudi's View
5
Rudi’s View: Resilience Shines, Forecasts Slide

Aug 23 2023 - Rudi's View

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
2
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
3
ResMed: Finding A Base?

Aug 15 2023 - Technicals
4
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
5
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
6
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
7
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
8
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Volpara Health Technologies

Apr 26 2023 - Small Caps
10
Dr Boreham’s Crucible: SDI

Mar 16 2023 - Small Caps